A Phase 2 Study to Evaluate Safety and Efficacy of AMB-05X in Subjects With Idiopathic Pulmonary Fibrosis

Phase 2 Withdrawn AmMax Bio, Inc.

RandomizedParallel-groupDouble-blindTreatment

Summary

AMB-053-01 is a randomized, placebo controlled, multicenter study which will enroll approximately 36 subjects ages 40 and older with IPF for 6 doses over a 24-week dosing period.

Timeline

Start: 2023-03
Primary completion: 2025-03
Completion: 2025-06

Outcome

Outcome not reported

Stopped: “to focus resources on other studies”

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	AMB-05X	Monoclonal antibody	—	—

A Phase 2 Study to Evaluate Safety and Efficacy of AMB-05X in Subjects With Idiopathic Pulmonary Fibrosis

Summary

Timeline

Outcome

Drugs

Indications